Microsatellite Instability – Response to Immunotherapy

Caris Molecular Intelligence® tumor profiling includes Microsatellite Instability (MSI) testing via Next-Generation sequencing (NGS). MSI is caused by failure of the DNA mismatch repair (MMR) system. High levels of MSI correlate to an increased neoantigen burden, which may indicate the tumor is more sensitive to immunotherapy. MSI status is reported on pages one and two of the MI Profile Report, as well as in the NGS section in the Appendix.

MSI-High Status Across Caris Molecular Intelligence Cases

Earlier studies have associated MSI-High status with benefit to immunotherapy in metastatic colorectal cancer. Recent data, however, show that MSI is a useful indicator for predicting response to pembrolizumab in any solid tumor type.¹

Traditionally, MSI is detected through polymerase chain reaction (PCR) by fragment analysis (FA) of five conserved satellite regions and comparing cancer tissue to normal tissue to identify differences in tandem repeats.³⁻⁴ To validate MSI testing via NGS, Caris evaluated more than 7,000 target microsatellite loci and compared the results from PCR for 2,189 cases across 26 different tumor types. These data were published in Cancer Medicine and demonstrated that MSI testing with Caris’ NGS platform is highly concordant with the traditional standard method of PCR-FA and is a more efficient and cost-effective approach to identifying patient candidates for immunotherapy.²

<table>
<thead>
<tr>
<th>Lineage</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>95.8%</td>
<td>99.4%</td>
<td>94.5%</td>
<td>99.2%</td>
</tr>
<tr>
<td>CRC</td>
<td>100.0%</td>
<td>99.9%</td>
<td>98.7%</td>
<td>98.7%</td>
</tr>
</tbody>
</table>

To order or learn more, visit www.CarisMolecularIntelligence.com.  
US: 888.979.8669 | MIClientServices@carisls.com  
Intl: 00 41 21 533 53 00 | EUCustomerServices@carisls.com


Traditionally, MSI is detected through polymerase chain reaction (PCR) by fragment analysis (FA) of five conserved satellite regions and comparing cancer tissue to normal tissue to identify differences in tandem repeats.
Unlock the Power of Immune Checkpoint Inhibitors

By harnessing the body’s immune system to detect and destroy tumor cells, immune checkpoint inhibitors are rapidly ushering in a new era of precision medicine.\(^1\)\(^-\)\(^4\) Although immune checkpoint inhibitors have demonstrated durable clinical responses across several tumor types, these therapies are costly and may present toxic side effects.\(^1\)\(^,\)\(^3\)\(^-\)\(^6\)

Understanding the relationships between TMB, MSI and PD-L1 can help oncologists make more informed immunotherapy decisions.\(^1\)\(^-\)\(^2\)\(^,\)\(^12\)

**Tumor mutational burden (TMB)** measures the total number of non-synonymous somatic mutations identified per megabase of the genome coding area. Tumors with high TMB likely harbor neoantigens and may respond more favorably to immunotherapies.\(^4\)\(^-\)\(^5\)\(^,\)\(^7\)

*Caris Experience data across all lineages: 33,000+

**Microsatellite instability (MSI)** is caused by failure of the DNA mismatch repair (MMR) system.\(^3\) MSI-High correlates to an increased neoantigen burden, which may indicate the tumor is more likely to respond favorably to immunotherapies.

*Caris Experience data across all lineages: 24,000+

**Programmed death ligand-1 (PD-L1)** is among the most important checkpoint proteins that mediate tumor-induced immune suppression through T-cell downregulation.\(^5\)\(^,\)\(^8\) PD-L1 expression may indicate a more likely response to immunotherapies.\(^2\)\(^,\)\(^9\)\(^-\)\(^11\)

*Caris Experience data across all lineages: 64,000+

Identify Patients More Likely to Respond to Immunotherapies through Comprehensive Genomic Profiling PLUS (CGP+) with Caris Molecular Intelligence.

---

To order or learn more, visit [www.CarisMolecularIntelligence.com](http://www.CarisMolecularIntelligence.com).

US: 888.979.8669 | MiClientServices@carisls.com

Int: 00 41 21 533 53 00 | EUCustomerServices@carisls.com

Caris Molecular Intelligence is a registered trademark of Caris MPI Inc. © 2018 Caris MPI Inc. All rights reserved. TN0310 v3 March 6, 2018